Sharemaestro Newsreel

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) reported a Q2 loss of $0.22 per share, outperforming the Zacks Consensus Estimate of a $0.24 loss. The company's revenues for the quarter ended June 2026 reached $1.78 million, surpassing estimates by 31.78%. Despite beating earnings and revenue expectations, CAMP …

Seer (SEER) Stock Faces Revenue Slump As Losses Stay Heavy

Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges

Eledon Pharmaceuticals' Q2 2026 Form 10-Q filing reveals significant concerns about its ability to continue as a going concern due to ongoing operating losses and the critical need for additional financing. The company anticipates continued losses and warns that failure to secure more capital …

Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4

Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours

Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …

Alumis (NASDAQ:ALMS) Issues Earnings Results

Alumis (NASDAQ:ALMS) reported earnings that missed analyst expectations, with an adjusted loss of $1.11 per share against a $0.73 consensus estimate and revenue of $1.66 million versus a $3.47 million forecast. Following the announcement, ALMS shares declined by $1.14 to $24.41. Despite some analyst …

Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Laura HansenChief Executive Officer - Ryan WattsChief Commercial Officer - Katie PengChief Operating and Financial Officer - Alexander SchuthChief Medical Officer, Head of Development - …

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. …

Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across …

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced a secondary public offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., an existing shareholder. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. William Blair, …

KKR Proposes Sale of 5 Million BridgeBio Pharma Shares in Offering

BridgeBio Pharma (BBIO) announced a secondary public offering of 5,000,000 shares of its common stock, to be sold by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not sell any shares in this transaction and will not receive any proceeds. The offering is subject …

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027

MediciNova (MNOV) reported a revenue increase to $0.5M in Q2 2026, primarily from Mayo ALS study services, while significantly narrowing its net loss to $2.3M. Research and development expenses decreased year-over-year, and the company's $25.4M in cash reserves are projected to fund operations until …

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

MediciNova: Q2 Earnings Snapshot

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock

Sarbani Chaudhuri, an insider at Rocket Pharmaceuticals (NASDAQ:RCKT), sold 4,701 shares of the company's stock for $16,453.50 on August 11th. This sale, made to cover tax obligations from vested equity awards, reduced her holdings by 1.76%. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong …

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips

Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …

Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants

Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …

Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares

Damora Therapeutics Director Andrew Cheng was granted stock options to purchase 30,350 ordinary shares on August 12, 2026, as revealed in a recent SEC Form 4 filing. The options have an exercise price of $31 per share and will vest in equal monthly installments …

Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results

Elicio Therapeutics (NASDAQ:ELTX) announced its quarterly earnings, reporting a loss of $0.43 per share, which surpassed analyst estimates by $0.11. Despite a 2.9% rise in shares following the announcement, the stock remains significantly below its 52-week high, with a market capitalization of $60.1 million. …

BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price

BioCardia's President and CEO, Peter Altman, recently purchased 1,900 shares of the company's common stock at a weighted average price of $0.92 per share. This open-market transaction, which occurred on August 13, 2026, increased his direct holdings to 375,785 shares. The purchase was not …

Scholar Rock (SRRK) Stock Looks Priced At A Premium Today

Aurinia Pharmaceuticals (AUPH) Earnings And Buyback Put Fair Value Back In Focus

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) reported a Q2 loss of $4.68 per share, missing the Zacks Consensus Estimate of a $3.18 loss, and revenues of -$1.47 million, significantly below the estimated figures. The company's shares have fallen 19.1% year-to-date, contrasting with the S&P 500's 13.2% gain. …

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Capricor Therapeutics (CAPR) Q2 Earnings Miss; Shares Rise Amid Mixed Signals

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Satellos Bioscience: Q2 Earnings Snapshot

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …